T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)

• Catherine Diefenbach,
• Opeyemi Jegede,
• Richard Ambinder,
• Jonathon Cohen,
• Michael Robertson,
• Kevin David,
• Ranjana Advani,
• Timothy Fenske,
• Stefan Barta,
• Neil Palmisiano,
• Jakub Svoboda,
• David Morgan,
• Reem Karmali,
• Brad Kahl,
• Stephen M. Ansell

Affiliations

Catherine Diefenbach

1 Perlmutter Cancer Center at NYU Langone Health

Opeyemi Jegede

2 ECOG-ACRIN Statistical Center Dana-Farber Cancer Institute Department of Data Sciences, Division of Biostatistics

Richard Ambinder

3 Dept of Oncology, Johns Hopkins University

Jonathon Cohen

4 Winship Cancer Institute, Emory University

Michael Robertson

5 School of Medicine, Indiana University

Kevin David

6 Division of Blood Disorders, Rutgers Cancer Institute of New Jersey

Ranjana Advani

7 Oncology Division, Stanford Cancer Institute

Timothy Fenske

8 Division of Hematology and Oncology, Froedtert and the Medical College of Wisconsin

Stefan Barta

9 Abramson Cancer Center, University of Pennsylvania

Neil Palmisiano

10 Sidney Kimmel Cancer Center, Thomas Jefferson University

Jakub Svoboda

9 Abramson Cancer Center, University of Pennsylvania

David Morgan

11 Vanderbilt University Medical Center

Reem Karmali

12 Robert H Lurie Comprehensive Cancer Center, Northwestern University

Brad Kahl

13 School of Medicine, Washington University St Louis

Stephen M. Ansell

14 Division of Hematology, Mayo Clinic